Skip to main content
Erschienen in: Intensive Care Medicine 9/2018

24.01.2018 | Understanding the Disease

Understanding thrombotic microangiopathies in children

verfasst von: Bérangère S. Joly, X. Long Zheng, Agnès Veyradier

Erschienen in: Intensive Care Medicine | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Excerpt

Thrombotic microangiopathy (TMA) is an ultra-rare syndrome. The incidence in children is estimated to be ~ 3.0 cases/106 population per year (Fig. 1). Very importantly, TMA belongs to the Thrombocytopenia Associated-Multi Organ Failure (TAMOF) syndromes and, therefore, its diagnosis should be considered in critically-ill children. Thus, intensive care physicians and nurses should be familiar with this rare but specific cause of TAMOF. TMA is life-threatening, resulting from ischemic multi-organ failure and characterised by its diversity and high ICU mortality rate, ~ 20%, despite appropriate treatment [1, 2]. The common features for TMA are microangiopathic haemolytic anemia (haemolysis, elevated lactate dehydrogenase, reduced haptoglobin, and fragmentation of red blood cells) and thrombocytopenia. Organ injury, associated with disseminated thrombi in the microcirculation, further supports the diagnosis of TMA. Differential diagnosis includes idiopathic thrombocytopenic purpura (ITP), Evans syndrome or malignancy-associated haematological abnormalities, in which organ injury is uncommon. Also, in contrast to disseminated intravascular coagulation (DIC), TMA are usually associated with normal prothrombin time (PT), activated partial thromboplastin time (aPTT), factor V and fibrinogen. Despite overlapping clinical and biological features, TMA has its distinct pathophysiology and therapeutic management [3]. The most frequent TMA syndromes reported in children are haemolytic uraemic syndrome (HUS), in which renal impairment is the prominent clinical feature. Thrombotic thrombocytopenic purpura (TTP), another TMA syndrome, also occurs in children, often associated with cerebral involvement. Secondary TMA are defined as TMA occurring with other comorbidities serving as the triggering events. These include severe infections, autoimmunity, haematopoietic progenitor cells or solid organ transplantations, malignancy and drugs. Therefore, the diagnosis of secondary TMA can be extremely challenging [1]. In this review, HUS and TTP will be discussed in more detail.
Literatur
1.
Zurück zum Zitat George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666CrossRefPubMed George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666CrossRefPubMed
2.
Zurück zum Zitat George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Am Soc Hematol Educ Progr 2012:604–609 George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Am Soc Hematol Educ Progr 2012:604–609
4.
Zurück zum Zitat Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMed Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMed
5.
6.
Zurück zum Zitat Fakhouri F, Zuber J, Frémeaux-Bacchi V et al (2017) Haemolytic uraemic syndrome. Lancet 390:681–696CrossRefPubMed Fakhouri F, Zuber J, Frémeaux-Bacchi V et al (2017) Haemolytic uraemic syndrome. Lancet 390:681–696CrossRefPubMed
7.
Zurück zum Zitat Grangé S, Bekri S, Artaud-Macari E et al (2015) Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 386:1011–1012CrossRefPubMed Grangé S, Bekri S, Artaud-Macari E et al (2015) Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 386:1011–1012CrossRefPubMed
8.
Zurück zum Zitat Zuber J, Fakhouri F, Roumenina LT et al (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657CrossRefPubMed Zuber J, Fakhouri F, Roumenina LT et al (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657CrossRefPubMed
9.
10.
Zurück zum Zitat Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859CrossRefPubMedPubMedCentral Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836–2846CrossRefPubMed Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836–2846CrossRefPubMed
12.
Zurück zum Zitat Saha M, McDaniel JK, Zheng XL (2017) Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapies. J Thromb Haemost 15:1889–1900CrossRefPubMed Saha M, McDaniel JK, Zheng XL (2017) Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapies. J Thromb Haemost 15:1889–1900CrossRefPubMed
13.
Zurück zum Zitat Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584CrossRefPubMed Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584CrossRefPubMed
14.
Zurück zum Zitat Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMedPubMedCentral Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494CrossRefPubMed Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494CrossRefPubMed
16.
Zurück zum Zitat Joly BS, Stepanian A, Leblanc T et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e537–e546CrossRefPubMed Joly BS, Stepanian A, Leblanc T et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e537–e546CrossRefPubMed
17.
Zurück zum Zitat Reese JA, Muthurajah DS, Kremer Hovinga JA et al (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676–1682CrossRefPubMed Reese JA, Muthurajah DS, Kremer Hovinga JA et al (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676–1682CrossRefPubMed
19.
Zurück zum Zitat Scully M, Knöbl P, Kentouche K et al (2017) Recombinant human ADAMTS-13: first in human study evaluating pharmacokinetics, safety and tolerability in cTTP patients. Blood 130:2055–2063CrossRefPubMedPubMedCentral Scully M, Knöbl P, Kentouche K et al (2017) Recombinant human ADAMTS-13: first in human study evaluating pharmacokinetics, safety and tolerability in cTTP patients. Blood 130:2055–2063CrossRefPubMedPubMedCentral
Metadaten
Titel
Understanding thrombotic microangiopathies in children
verfasst von
Bérangère S. Joly
X. Long Zheng
Agnès Veyradier
Publikationsdatum
24.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 9/2018
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-018-5059-2

Weitere Artikel der Ausgabe 9/2018

Intensive Care Medicine 9/2018 Zur Ausgabe

Imaging in Intensive Care Medicine

Acute sulfamethoxazole-induced crystal nephropathy

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.